Shares of Eli Lilly (NYSE: LLY) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with a market cap of over $500 billion is in a sharp drawdown due to ...

You can finally watch one of the goriest r-rated horror movies on streaming ...

(CNN) — In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, while the Nasdaq eked out a record closing high.

Eli Lilly's oral GLP-1 drug orforglipron shows promise in weight loss, with significant results in a 72-week trial, aiming for 2025 global approval.

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Lilly's late-stage results for its experimental oral obesity drug raised concerns.

Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase ...

Eli Lilly and Company has confirmed it’s selling its manufacturing site in Branchburg. The decision was made following a comprehensive assessment, which concluded the Branchburg plant’s ...